Literature DB >> 10213232

Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage.

F Vikhanskaya1, G Colella, M Valenti, S Parodi, M D'Incalci, M Broggini.   

Abstract

We have studied the possible interactions between the mismatch repair system and p53 in a human colon cancer cell line, HCT-116 (known to have a homozygous mutation in mismatch repair gene hMLH1 on chromosome 3) and in a clone obtained after insertion of a single copy of chromosome 3 (HCT-116+ ch3). Loss of DNA mismatch repair activity resulted in resistance to cisplatin (DDP). p53 accumulated differently in these cell lines after treatment with DDP. Initially at similar high levels after DDP treatment, p53 maintained the increase in HCT-116 cells, even 72-96 h after drug exposure, whereas HCT-116+ch3 mismatch-proficient cell line p53 declined to basal levels after 48 h. The higher levels of p53 in mismatch-deficient HCT-116 cells were accompanied by increased transcriptional activity as assessed by the gel-retardation assay and by activation of a promoter containing a p53 DNA binding site. To better understand the role of p53, if any, in cell sensitivity to DDP, we disrupted p53 in both cell lines by stable transfection with the human papillomavirus type 16 E6 gene. HCT-116/E6 cells were more sensitive to DDP than the parental cell line, whereas HCT-116+ch3/E6 were fairly similar to HCT-116+ch3 with normal p53 function. Although in our system the transfer of the entire chromosome 3 was used (thus not excluding a possible role of other genes localized on this chromosome), our data indicate that p53 can cooperate with the mismatch repair system. In fact, the lack of hLMH1, at least in these cells, enhances the role of p53 in protecting the cells from DDP-induced DNA damage.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10213232

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  9 in total

1.  Identification of the mismatch repair genes PMS2 and MLH1 as p53 target genes by using serial analysis of binding elements.

Authors:  Jiguo Chen; Ivan Sadowski
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-21       Impact factor: 11.205

2.  Functional and physical interaction between the mismatch repair and FA-BRCA pathways.

Authors:  Stacy A Williams; James B Wilson; Allison P Clark; Alyssa Mitson-Salazar; Andrei Tomashevski; Sahana Ananth; Peter M Glazer; O John Semmes; Allen E Bale; Nigel J Jones; Gary M Kupfer
Journal:  Hum Mol Genet       Date:  2011-08-24       Impact factor: 6.150

3.  Trp53 regulates Notch 4 signaling through Mdm2.

Authors:  Youping Sun; Malgorzata Klauzinska; Robert J Lake; Joseph M Lee; Stefania Santopietro; Ahmed Raafat; David Salomon; Robert Callahan; Spyros Artavanis-Tsakonas
Journal:  J Cell Sci       Date:  2011-04-01       Impact factor: 5.285

Review 4.  Resistance mechanisms of gastrointestinal cancers: why does conventional chemotherapy fail?

Authors:  F Gieseler; P Rudolph; G Kloeppel; U R Foelsch
Journal:  Int J Colorectal Dis       Date:  2003-05-28       Impact factor: 2.571

5.  Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer.

Authors:  Michael A Batey; Yan Zhao; Suzanne Kyle; Caroline Richardson; Andrew Slade; Niall M B Martin; Alan Lau; David R Newell; Nicola J Curtin
Journal:  Mol Cancer Ther       Date:  2013-03-19       Impact factor: 6.261

6.  Ascorbate up-regulates MLH1 (Mut L homologue-1) and p73: implications for the cellular response to DNA damage.

Authors:  M Valeria Catani; Antonio Costanzo; Isabella Savini; Massimo Levrero; Vincenzo de Laurenzi; Jean Y J Wang; Gerry Melino; Luciana Avigliano
Journal:  Biochem J       Date:  2002-06-01       Impact factor: 3.857

Review 7.  Platinum Complexes in Colorectal Cancer and Other Solid Tumors.

Authors:  Beate Köberle; Sarah Schoch
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

8.  Screening of drugs to counteract human papillomavirus 16 E6 repression of E-cadherin expression.

Authors:  Zarina J D'Costa; Cheng-Mee Leong; Justin Shields; Charles Matthews; Merilyn H Hibma
Journal:  Invest New Drugs       Date:  2012-02-23       Impact factor: 3.651

9.  Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2.

Authors:  A Fedier; U B Ruefenacht; V A Schwarz; U Haller; D Fink
Journal:  Br J Cancer       Date:  2002-10-21       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.